Insights - This morning Fennec (FENC) announced that the company completed their NDA filing to FDA & application to EMA (read here). Surprising EMA SubmissionEuropean submission was a pleasant surprise, as … Continue Reading
Premium: Read NowInsights - La Jolla has been on a tear in the new year and since we first covered the name in early December at a price around … Continue Reading
Premium: Read NowInsights - Stakeholders in Alzheimer’s Disease have been fixated on the amyloid thesis, which has resulted in underwhelming results for the past decade. 2020 is shaping up … Continue Reading
Premium: Read NowInsights - Acasti reported that their first Phase 3 trial of Capre did not reach statistical significance due to an unusually large placebo effect. ACST is down … Continue Reading
Read NowInsights - La Jolla (LJPC) announced preliminary Giapreza sales for 2019. The stock has traded up about 35% today as figures are showing that Giapreza sales execution is on … Continue Reading
Premium: Read NowInsights - Below we’ve outlined our watchlist with 3 main names that we think will outperform in the new year. The 3 names are Iovance, Xenon and … Continue Reading
Premium: Read NowInsights - Thesis/Strategy For Existing Names Fennec (FENC) – Read historical Fennec analysis here Fennec is preparing a NDA submission for Pedmark in chemo-induced pediatric hearing loss. The company … Continue Reading
Premium: Read Now
